Table 2.
n (%) or mean (SD) | P value | |||
---|---|---|---|---|
State policy status | No marijuana policy at index | Medical marijuana policy only at index | Medical and recreational marijuana policy at index | |
Among entire sample (n = 141,711) | n = 80,955 | n = 56,494 | n = 4262 | |
Opioid index prescription | 47,946 (59.2%) | 32,323 (57.2%) | 2983 (70.0%) | < 0.001 |
Follow-up opioid prescription | 64,865 (80.1%) | 42,755 (75.7%) | 3683 (86.4%) | < 0.001 |
Among those with new pain prescriptions (n = 86,985) | n = 48,217 | n = 36,188 | n = 2580 | |
Opioid index prescription | 29,455 (61.1%) | 20,646 (57.1%) | 1868 (72.4%) | < 0.001 |
Among those prescribed opioids at index (n = 83,252) | n = 47,946 | n = 32,323 | n = 2983 | |
Index opioid days’ supply > 7 | 18,044 (37.6%) | 12,171 (37.7%) | 995 (33.4%) | < 0.001 |
Cumulative days’ supply ≥ 90 | 1935 (4.0%) | 1269 (2.5%) | 102 (4.0%) | < 0.001 |
Mean daily index MED (SD) | 48.7 (70.2) | 51.9 (90.5) | 59.5 (89.5) | < 0.001 |
Mean index opioid days’ supply (SD) | 11.3 (14.1)† | 11.3 (13.9)† | 10.9 (15.1)† | NS |
*All data were statistically significant at the P < 0.001 across groups, except for cells marked with a note indicating otherwise
†Not significantly different across groups
Follow-up opioid defined as any opioid prescription within the 2-year follow-up period. SD standard deviation, MED morphine equivalent dose, NS not significant